Coronaviruses: Severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers

Current Opinion in Infectious Diseases

Volumn 27, Issue 5, 2014, Pages 411-417

  Al Tawfiq, Jaffar A ^d,e   Zumla, Alimuddin ^a,c   Memish, Ziad A ^a,b  

^a MINISTRY OF HEALTH   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d DHAHRAN HEALTH CENTER   (Saudi Arabia)

^e INDIANA UNIVERSITY   (United States)

Author keywords

coronaviruses; MERS CoV; Middle East; SARS CoV; travel

Indexed keywords

ALPHA INTERFERON; CHLOROQUINE; CHLORPROMAZINE; CYCLOPHILIN INHIBITOR; LOPERAMIDE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEUTRALIZING ANTIBODY; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS VACCINE; CYTOCHROME P450 3A INHIBITOR;

ANTIVIRAL THERAPY; ASIA; BAT; CAMEL; COMORBIDITY; CORONAVIRUS; CORONAVIRUS INFECTION; DIAGNOSTIC TEST; EUROPE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR DIAGNOSIS; NONHUMAN; PHYSICIAN; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; RADIOGRAPHY; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TRAVEL; UNITED STATES; VACCINATION; VIRUS DETECTION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; ZOONOSIS; AIRCRAFT; CROSS INFECTION; EPIDEMIOLOGY; HAND WASHING; IMMUNOLOGY; ISOLATION AND PURIFICATION; ORGANIZATION AND MANAGEMENT; PANDEMIC; PATHOGENICITY; PROCEDURES; TIME; TRANSMISSION;

AIRCRAFT; ANTIBODIES, NEUTRALIZING; CROSS INFECTION; CYTOCHROME P-450 CYP3A INHIBITORS; EUROPE; GUIDELINES AS TOPIC; HAND HYGIENE; HUMANS; INFECTION CONTROL; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TIME FACTORS; TRAVEL; UNITED STATES;

EID: 84906939264     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000089     Document Type: Review

References (94)

1. de Groot RJ, Baker SC, Baric R, et al. 'Family coronaviridae'. In: King AMQ, Lefkowitz E, Adams MJ, Carstens EB, editors. Ninth Report of the International Committee on Taxonomy of Viruses. Oxford: Elsevier; 2011. pp. 806-828.
2. Lee N, Hui DS, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1986-1994.
3. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-1820.
4. Hui DS, Memish Z, Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med 2014; 20:233-241. doi: 10.1097/MCP.0000000000000046.
5. Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004; 303:1666-1669.
6. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1977-1985.
7. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348:1995-2005.
8. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto area. JAMA 2003; 289:2801-2809.
9. Centers for Disease Control Prevention. Severe acute respiratory syndrome-Singapore, 2003. MMWR 2003; 52:405-411.
10. Parashar UD, Anderson LJ. Severe acute respiratory syndrome: review and lessons of the 2003 outbreak. Int J Epidemiol 2004; 33:628-634.
11. WHO. Cumulative Number of Reported Probable Cases of SARS. http://www.who.int/csr/sars/country/2003-07-04/en/. [Accessed 10 May 2014]
12. Centers for Disease Control Prevention (CDC). Severe respiratory illness associated with a novel coronavirus: Saudi Arabia and Qatar, 2012. Morb Mortal Wkly Rep 2012; 61:820.
13. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013; 87:7790-7792.
14. Al-Abdallat MM, Payne DC, Alqasrawi S, et al. Hospital-associated outbreak of Middle East Respiratory Syndrome Coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; pii: ciu359. [Epub ahead of print]
15. Hijawi B, Abdallat M, Sayaydeh A, et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Med H J 2013; 19:S12-S18.
16. Health Protection Agency (HPA) UK Novel Coronavirus Investigation team. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 2013; 18:20427.
17. ProMED-mail. MERS-CoV-Eastern Mediterranean (07): Tunisiaex Saudi Arabia/Qatar, fatal, WHO. 22 May 2013. http://www.promedmail.org/direct. php?id=20130522.1730663. [Accessed 19 June 2014]
18. Memish ZA, Cotten M, Watson SJ, et al. Community case clusters of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study. Int J Infect Dis 2014; 23:63-68.
19. Brown C. MERS differs from SARS, say experts. CMAJ 2014; 186:E303-E304.
20. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-454.
21. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-254.
22. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel humancoronavirus MERS-CoV and its receptor CD26. Nature 2013; 500:227-231.
23. Mü ller A, Raj VS, Muth D, et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012; 3: e00515-12.
24. Chan JF, Chan KH, Choi GK, et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013; 207:1743-1752.
25. Coburn BJ, Blower S. Predicting the potential for within-flight transmission and global dissemination of MERS. Lancet Infect Dis 2014; 14:99.
26. Bialek SR, Allen D, Alvarado-Ramy F, et al. First confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United States, updated information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities-May. Morb Mortal Wkly Rep 2014; 63:431-436.
27. Olsen SJ, Chang HL, Cheung TY, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med 2003; 349:2416-2422.
28. Desenclos JC, van der Werf S, Bonmarin I, et al. Introduction of SARS in France, March-April, 2003. Emerg Infect Dis 2004; 10:195-200.
29. Wilder-Smith A, Leong HN. A case of in-flight transmission of severe acute respiratory syndrome (SARS): SARS serology positive. J Travel Med 2004; 11:130.
30. Vogt TM, Guerra MA, Flagg EW, et al. Risk of severe acute respiratory syndrome-associated coronavirus transmission aboard commercial aircraft. J Travel Med 2006; 13:268-272.
31. Wilder-Smith A, Paton NI, Goh KT. Low risk of transmission of severe acute respiratory syndrome on airplanes: the Singapore experience. Trop Med Int Health 2003; 8:1035-1037.
32. Flint J, Burton S,Macey JF, et al. Assessment of in-flight transmission of SARS-results of contact tracing, Canada. Can Commun Dis Rep 2003; 29:105-110.
33. Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all1755 patients. Ann Intern Med 2004; 141:662-673.
34. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407-416.
35. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752-761.
36. Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest 2003; 124:12-15.
37. Wong KT, Antonio GE, Hui DS, et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003; 228:401-406.
38. Al-Tawfiq JA, Hinedi K, Ghandour J, et al. Middle East respiratory syndromecoronavirus (MERS-CoV): a case-control study of hospitalized patients. Clin Infect Dis 2014; 59:160-165.
39. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160:389-397.
40. Hui DS, Chan PK. Severe acute respiratory syndrome and coronavirus. Infect Dis Clin North Am 2010; 24:619-638.
41. Fan CK, Yieh KM, Peng MY, et al. Clinical and laboratory features in the early stage of severe acute respiratory syndrome. J Microbiol Immunol Infect 2006; 39:45-53.
42. Rainer TH, Lee N, Ip M, et al. Features discriminating SARS from other severe viral respiratory tract infections. Eur J Clin Microbiol Infect Dis 2007; 26:121-129.
43. Liu CL, Lu YT, Peng MJ, et al. Clinical and laboratory features of severe acute respiratory syndrome vis-a-vis onset of fever. Chest 2004; 126:509-517.
44. Christian MD, Poutanen SM, Loutfy MR, et al. Severe acute respiratory syndrome. Clin Infect Dis 2004; 38:1420-1427.
45. TheWHOResearch MERS-CoV Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013; 5.
46. Penttinen PM, Kaasik-Aaslav K, Friaux A, et al. Taking stock of the first133 MERS coronavirus cases globally-is the epidemic changing? Euro 340 Surveill 2013; 18:39.
47. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, et al. Respiratory tract samples, viral load and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 2014; pii: jiu292. [Epub ahead of print]
48. Kan B, Wang M, Jing H, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus like virus in palm civets at an animal market and on farms. J Virol 2005; 79:11892-11900.
49. Tu C, Crameri G, Kong X, et al. Antibodies to SARS coronavirus in civets. Emerg Infect Dis 2004; 10:2244-2248.
50. Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res 2008; 133:74-87.
51. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302:276-278.
52. van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirusassociated with acute respiratory distress syndrome in humans. MBio 2012; 3: e00473-12.
53. Annan A, Baldwin HJ, Corman VM, et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 2013; 19:456-459.
54. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; 19:1819-1823.
55. Reusken CB, Haagmans BL, Muller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; 13:859-866.
56. Haagmans BL, Al Dhahiry SH, Reusken CB, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2013; 14:140-145.
57. Nowotny N, Kolodziejek J. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Euro Surveill 2014; 19: 20781.
58. Briese T, Mishra N, Jain K, et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. MBio 2014; 5:; e01146-14.
59. Hemida MG, Perera RA, Wang P, et al. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 2013; 18:20659.
60. Reusken CB, Ababneh M, Raj VS, et al. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill 2013; 18:20662.
61. CDC. Middle East Respiratory Syndrome (MERS). http://www.cdc.gov/ CORONAVIRUS/MERS/INDEX.HTML. [Accessed 28 May 2014]
62. Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September. Euro Surveill 2012; 17:20290.
63. CDC. Middle East Respiratory Syndrome. http://www.cdc.gov/CORONAVIRUS/ MERS/US.html. [Accessed 22 May 2014]
64. Brosseau LM and Jones R. COMMENTARY: Protecting health workers from airborne MERS-CoV-Learning from SARS. Center for Infectious Disease Research and Policy. Posted May 19, 2014. http://www.cidrap.umn.edu/news-perspective/2014/ 05/commentary-protecting-health-workers-airbornemers-cov-learning-sars. [Accessed 21 May 2014]
65. National Institute for Public Health and the Environment. The MERScoronavirus in the Netherlands. http://www.rivm.nl/en/Documents-and- publications/Common-and-Present/Newsmessages/2014/The-MERS-coro navirus-in-the-Netherlands. [Accessed 22 May 2014]
66. European CDC. Epidemiological update: Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.ecdc.europa.eu/en/press/news/-lay outs/forms/News-DispForm.aspxList=8db7286c-fe2d-476c-9133-18ff4cb 1b568&ID=1002. [Accessed 22 May 2014]
67. CDC. Middle East Respiratory Syndrome. http://wwwnc.cdc.gov/travel/ notices/alert/coronavirus-saudi-arabia-qatar. [Accessed 28 May 2014]
68. Al-Tawfiq JA, Memish ZA. Mass gatherings and infectious diseases: prevention, detection, and control. Infect Dis Clin North Am 2012; 26:725-737.
69. Memish ZA, Zumla A, Alhakeem RF, et al. Hajj: infectious disease surveillance and control. Lancet 2014; 383:2073-2082.
70. Memish ZA, Zumla A, Al-Tawfiq JA. How great is the risk of Middle East respiratory syndrome coronavirus to the global population Expert Rev Anti Infect Ther 2013; 11:979-981.
71. Novel coronavirus-Eastern Mediterranean (03): Saudi comment, 12 February 2013. ProMed, 2013, archive number 20130212.1540011
72. Gautret P, Charrel R, Belhouchat K, et al. Lack of nasal carriage of novel corona virus (HCoVEMC) in French Hajj pilgrims returning from the Hajj 2012, despite a high rate of respiratory symptoms. Clin Microbiol Infect 2013; 19:e315-e317.
73. Memish ZA, Assiri A, Almasri M, et al. Prevalence of MERS-CoV nasal carriage and compliance with the Saudi health recommendations among pilgrims attending the 2013 Hajj. J Infect Dis 2014. [Epub ahead of print]
74. Memish ZA, Al-Rabeeah AA. Health conditions of travellers to Saudi Arabia for the pilgrimage to Mecca (Hajj and Umra) for 1434 (2013). J Epidemiol Glob Health 2013; 3:59-61.
75. Momattin H, Mohammed K, Zumla A, et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013; 17:e792-e798.
76. Al-Tawfiq JA, Memish ZA. What are our pharmacotherapeutic options for MERS-CoV Expert Rev Clin Pharmacol 2014; 7:235-238.
77. ISARIC, International Severe Acute Respiratory Emerging Infection Consortium. Clinical Decision Making Tool for Treatment of MERS-CoV v.1.0, 18 June, 2013. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317139281416. [Accessed 21 May 2014]
78. Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of MERS-CoV by human monoclonal antibodies. J Virol 2014; 88:7796-7805.
79. Tang XC, Agnihothram SS, Jiao Y, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 2014; 111:E2018-E2026.
80. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory coronavirus infection. Antimicrob Agents Chemother 2014; pii: AAC.03036-14. [Epub ahead of print]
81. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDAapproved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; pii: AAC.03011-14. [Epub ahead of print.
82. Adedeji AO, Singh K, Kassim A, et al. Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS coronaviruses. Antimicrob Agents Chemother 2014; pii: AAC.02994-14. [Epub ahead of print]
83. Song F, Fux R, Provacia LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2003; 87:11950-11954.
84. Coleman CM, Liu YV, Mu H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014; 32:3169-3174.
85. Du L, Zhao G, Yang Y, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in MERS-CoV spike protein. J Virol 2014; 88:7045-7053.
86. Ma C, Li Y, Wang L, Zhao G, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32:2100-2108.
87. Du L, Kou Z, Ma C, Tao X, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013; 8:e81587.
88. Almazán F, DeDiego ML, Sola I, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 2013; 4:; e00650-13.
89. Aburizaiza AS, Mattes FM, Azhar EI, et al. Investigation of anti-Middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, Fall 2012. J Infect Dis 2014; 209:243-246.
90. Gierer S, Hofmann-Winkler H, Albuali WH, et al. Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi Arabia. Emerg Infect Dis 2013; 19:2034-2036.
91. Saudi Ministry of Health. Novel Coronavirus. http://www.moh.gov.sa/En/ CoronaNew/PressReleases/Pages/default.aspx. [Accessed 28 May 2014]
92. Zumla A, Hui DS. Infection control and MERS-CoV in health-care workers. Lancet 2014; 383:1869-1871.
93. WHO. Global alert and response. Middle East respiratory syndrome coronavirus (MERS-CoV)-update. May 15, 2014. http://www.who.int/csr/don/2014-05- 15-mers/en/. [Accessed 22 May 2014]
94. CDC. Interim infection prevention and control recommendations for hospitalized patients with Middle East respiratory syndrome coronavirus (MERSCoV). May 15, 2014. http://www.cdc.gov/coronavirus/mers/ infectionprevention-control.html#infection-prevention [Accessed 22 May 2014]